Where Can I Buy Scopolamine Transdermal Patches Near Me

What is Transderm Scop and how is it used?

Transderm Scop is a prescription medicine used to treat the symptoms of nausea or vomiting caused by movement sickness or from anesthesia. Transderm Scop may be used alone or with other medications.

Transderm Scop belongs to a class of drugs called Antiemetic Agents.

Information technology is not known if Transderm Scop is safe and effective in children.

What are the possible side effects of Transderm Scop?

Transderm Scop may cause serious side effects including:

• severe dizziness,
• confusion,
• agitation,
• extreme fright,
• hallucinations,
• unusual thoughts or behavior,
• convulsions (seizures),
• centre pain or redness,
• blurred vision,
• dilated pupils,
• decreased urination,
• painful or hard urination,
• stomach hurting,
• nausea, and
• vomiting

Get medical assist right away, if you have any of the symptoms listed above.

The most common side effects of Transderm Scop include:

• dry out mouth,
• sore throat,
• blurred vision or other centre problems,
• drowsiness,
• dizziness,
• confusion, and
• feeling agitated or irritable

Tell the doctor if you have any side consequence that bothers y'all or that does non go abroad.

These are not all the possible side effects of Transderm Scop. For more than information, ask your doctor or pharmacist.

Phone call your medico for medical communication about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Clarification

The Transderm Scop® (scopolamine) transdermal system is a round flat patch designed for continuous release of scopolamine following application to an area of intact skin on the head, behind the ear. Each organisation contains 1.5 mg of scopolamine base. Scopolamine is α -(hydroxymethyl) benzeneacetic acrid 9-methyl-3-oxa-9-azatricyclo [3.3.1.0^two,iv ] non-seven-yl ester. The empirical formula is C₁₇H₂₁NO₄ and its structural formula is:

Scopolamine is a viscous liquid that has a molecular weight of 303.35 and a pKa of 7.55-seven.81. The Transderm Scop system is a picture 0.two mm thick and 2.5 cm², with iv layers. Proceeding from the visible surface towards the surface attached to the peel, these layers are: (ane) a backing layer of tan-colored, aluminized, polyester flick; (2) a drug reservoir of scopolamine, light mineral oil, and polyisobutylene; (iii) a microporous polypropylene membrane that controls the charge per unit of delivery of scopolamine from the organisation to the pare surface; and (iv) an adhesive conception of mineral oil, polyisobutylene, and scopolamine. A protective pare strip of siliconized polyester, which covers the adhesive layer, is removed before the system is used. The inactive components, lite mineral oil (12.4 mg) and polyisobutylene (11.4 mg), are not released from the system.

Cross section of the system:

INDICATIONS

Transderm Scop is indicated in adults for the prevention of:

• nausea and vomiting associated with motion sickness.
• mail-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery.

DOSAGE AND Administration

Important Awarding And Removal Instructions

• Each Transderm Scop transdermal organisation is formulated to deliver in vivo approximately 1 mg of scopolamine over 3 days.
• Only wear one transdermal system at any fourth dimension.
• Do not cut the transdermal organisation.
• Employ the transdermal system to the skin in the postauricular area (hairless expanse backside one ear).
• Later on the transdermal organization is applied on the dry skin backside the ear, launder hands thoroughly with soap and water and dry hands [meet WARNINGS AND PRECAUTIONS].
• If the transdermal system becomes displaced, discard the transdermal arrangement, and use a new transdermal system on the hairless area behind the other ear.
• Upon removal, fold the used transdermal system in one-half with the sticky side together, and discard in household trash in a style that prevents accidental contact or ingestion by children, pets or others.

Recommended Adult Dosage

Motility Sickness

Apply one Transderm Scop transdermal system to the hairless expanse behind one ear at to the lowest degree 4 hours before the antiemetic result is required – for employ upward to three days. If therapy is required for longer than 3 days, remove the first transdermal system and apply a new Transderm Scop transdermal system behind the other ear.

PONV

For surgeries other than cesarean section:

Utilise 1 Transderm Scop transdermal organization the evening before scheduled surgery. Remove the transdermal arrangement 24 hours following surgery.

HOW SUPPLIED

Dosage Forms And Strengths

Transdermal system: a circular, flat, tan-colored transdermal arrangement imprinted with "Scopolamine 1 mg/3 days"

Storage And Handling

Transderm Scop (scopolamine transdermal arrangement) 1 mg/3 days is available as the post-obit:

Carton of iv transdermal systems, packaged into individual foil pouches. NDC 0067-4346-04

Store at controlled room temperature between 68°F to 77°F (twenty°C to 25°C).

Store pouch(es) in an upright position.

Do non curve or roll pouch(es).

Wash hands thoroughly with soap and water immediately subsequently handling the transdermal system. Upon removal, fold the used transdermal organisation in half with the sticky side together, and discard in household trash in a fashion that prevents accidental contact or ingestion by children, pets or others [see DOSAGE AND Administration, WARNINGS AND PRECAUTIONS].

Manufactured by: ALZA Corporation, Vacaville, CA 95688. Revised: Feb 2019

QUESTION

Well-nigh how much does an developed human being encephalon counterbalance? See Reply

SIDE Furnishings

The post-obit serious adverse reactions are described elsewhere in labeling:

• Acute Angle Closure Glaucoma [run into WARNINGS AND PRECAUTIONS]
• Neuropsychiatric Adverse Reactions [encounter WARNINGS AND PRECAUTIONS]
• Eclamptic Seizures in Meaning Women [come across WARNINGS AND PRECAUTIONS]
• Gastrointestinal and Urinary Disorders [see WARNINGS AND PRECAUTIONS]
• Drug Withdrawal/Post-Removal Symptoms [see WARNINGS AND PRECAUTIONS]
• Blurred Vision [run across WARNINGS AND PRECAUTIONS]
• MRI Peel Burns [see WARNINGS AND PRECAUTIONS]

Clinical Trials Feel

Because clinical trials are conducted under widely varying atmospheric condition, adverse reaction rates observed in the clinical trials of a drug cannot exist directly compared to rates in the clinical trials of another drug and may non reflect the rates observed in practice.

Motion Sickness

The about common adverse reaction (approximately two thirds) was dry oral cavity. Less common adverse reactions, included drowsiness (less than one sixth), blurred vision and dilation of the pupils.

PONV

Common adverse reactions, occurring in at least 3% of patients in PONV clinical trials are shown in Tabular array 1.

Table one Common Adverse Reactions* in Surgical Patients for the Prevention of PONV

	Transderm Scop % (N = 461)	Placebo % (Due north = 457)
Dry oral fissure	29	16
Dizziness	12	7
Somnolence	eight	4
Agitation	half-dozen	4
Visual Impairment	5	three
Confusion	iv	3
Mydriasis	4	0
Pharyngitis	3	2
*occurring in at least 3% of patients and at a charge per unit higher than placebo

Postmarketing Experience

The following adverse reactions have been identified during post-approving use of scopolamine transdermal organisation. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Psychiatric disorders: astute psychosis including: hallucinations, disorientation, and paranoia

Nervous system disorders: headache, amnesia, coordination abnormalities, speech disorder, disturbance in attention, restlessness

General disorders and administration site atmospheric condition: application site burning

Eye disorders: dry out eyes, middle pruritus, angle closure glaucoma, amblyopia, eyelid irritation

Skin and subcutaneous tissue disorders: rash generalized, peel irritation, erythema

Renal and urinary disorders: dysuria

Ear and labyrinth disorders: vertigo

DRUG INTERACTIONS

Drugs Causing Key Nervous Organization (CNS) Adverse Reactions

The concurrent apply of Transderm Scop with other drugs that cause CNS agin reactions of drowsiness, dizziness or disorientation (east.g., sedatives, hypnotics, opiates, anxiolytics and alcohol) or accept anticholinergic properties (e.grand., other belladonna alkaloids, sedating antihistamines, meclizine, tricyclic antidepressants, and muscle relaxants) may potentiate the effects of Transderm Scop [run into WARNINGS AND PRECAUTIONS]. Either Transderm Scop or the interacting drug should be chosen, depending on the importance of the drug to the patient. If the interacting drug cannot be avoided, monitor patients for CNS adverse reactions.

Anticholinergic Drugs

Concomitant use of scopolamine with other drugs having anticholinergic backdrop may increase the risk of CNS adverse reactions [see Drugs Causing Primal Nervous System (CNS) Adverse Reactions], abdominal obstruction and/or urinary retention. Consider more frequent monitoring during handling with Transderm Scop in patients receiving anticholinergic drugs [run into WARNINGS AND PRECAUTIONS].

Oral Drugs Captivated In The Stomach

Transderm Scop, as an anticholinergic, may delay gastric and upper gastrointestinal motility and, therefore, the rate of absorption of other orally administered drugs. Monitor patients for modified therapeutic upshot of concomitant orally administered drugs with a narrow therapeutic alphabetize.

Interaction With Gastric Secretion Examination

Scopolamine will interfere with the gastric secretion test. Discontinue Transderm Scop x days prior to testing.

Drug Corruption And Dependence

Controlled Substance

Transderm Scop contains scopolamine, which is not a controlled substance.

Dependence

Termination of Transderm Scop, usually subsequently several days of apply, may effect in withdrawal symptoms such as disturbances of equilibrium, dizziness, nausea, vomiting, abdominal cramps, sweating, headache, mental confusion, muscle weakness, bradycardia and hypotension. These withdrawal symptoms signal that scopolamine, like other anticholinergic drugs, may produce physical dependence. The onset of these symptoms, generally 24 hours or more afterward the transdermal arrangement has been removed, can be astringent and may require medical intervention [come across WARNINGS AND PRECAUTIONS].

WARNINGS

Included as part of the "PRECAUTIONS" Department

PRECAUTIONS

Acute Bending Closure Glaucoma

The mydriatic effect of scopolamine may cause an increment in intraocular pressure resulting in acute angle closure glaucoma. Monitor intraocular pressure in patients with open bending glaucoma and arrange glaucoma therapy during Transderm Scop use, equally needed. Suggest patients to immediately remove the transdermal organization and contact their healthcare provider if they experience symptoms of acute bending closure glaucoma (eastward.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema).

Neuropsychiatric Adverse Reactions

Psychiatric Adverse Reactions

Scopolamine has been reported to exacerbate psychosis. Other psychiatric reactions have also been reported, including acute toxic psychosis, agitation, spoken communication disorder, hallucinations, paranoia, and delusions [see Adverse REACTIONS]. Monitor patients for new or worsening psychiatric symptoms during treatment with Transderm Scop. Also, monitor patients for new or worsening psychiatric symptoms during concomitant treatment with other drugs that are associated with similar psychiatric furnishings [see DRUG INTERACTIONS].

Seizures

Seizures and seizure-similar activity have been reported in patients receiving scopolamine. Weigh this potential risk against the benefits before prescribing Transderm Scop to patients with a history of seizures, including those receiving anti-epileptic medication or who accept take chances factors that can lower the seizure threshold.

Cognitive Adverse Reactions

Scopolamine can cause drowsiness, disorientation, and confusion. Discontinue Transderm Scop if signs or symptoms of cognitive impairment develop. Elderly and pediatric patients may be more sensitive to the neurological and psychiatric furnishings of Transderm Scop. Consider more frequent monitoring during treatment with Transderm Scop in elderly patients [run across Use In Specific Populations]. Transderm Scop is not approved for use in pediatric patients [see Use In Specific Populations].

Hazardous Activities

Transderm Scop may impair the mental and/or physical abilities required for the functioning of hazardous tasks such equally driving a motor vehicle, operating machinery or participating in underwater sports. Concomitant use of other drugs that crusade fundamental nervous system (CNS) adverse reactions (e.g., alcohol, sedatives, hypnotics, opiates, and anxiolytics) or have anticholinergic backdrop (east.1000., other belladonna alkaloids, sedating antihistamines, meclizine, tricyclic antidepressants, and muscle relaxants) may increase this effect [encounter DRUG INTERACTIONS]. Inform patients not to operate motor vehicles or other unsafe machinery or participate in underwater sports until they are reasonably certain that Transderm Scop does not touch on them adversely.

Eclamptic Seizures In Meaning Women

Eclamptic seizures accept been reported in pregnant women with severe preeclampsia presently after injection of intravenous and intramuscular scopolamine [run across Use In Specific Populations]. Avert use of Transderm Scop in patients with astringent preeclampsia.

Gastrointestinal And Urinary Disorders

Scopolamine, due to its anticholinergic properties, can decrease gastrointestinal motility and crusade urinary retention. Consider more than frequent monitoring during handling with Transderm Scop in patients suspected of having abdominal obstruction, patients with pyloric obstruction or urinary bladder neck obstacle and patients receiving other anticholinergic drugs [meet DRUG INTERACTIONS]. Discontinue Transderm Scop in patients who develop difficulty in urination.

Drug Withdrawal/Postal service-Removal Symptoms

Discontinuation of Transderm Scop, ordinarily afterwards several days of use, may result in withdrawal symptoms, such equally disturbances of equilibrium, dizziness, nausea, vomiting, intestinal cramps, sweating, headache, mental defoliation, musculus weakness, bradycardia and hypotension. The onset of these symptoms is generally 24 hours or more after the transdermal arrangement has been removed. Instruct patients to seek medical attention if they experience severe symptoms.

Blurred Vision

Scopolamine can cause temporary dilation of the pupils resulting in blurred vision if it comes in contact with the eyes.

Advise patients to launder their hands thoroughly with lather and water and dry their hands immediately afterward handling the transdermal system [see DOSAGE AND ADMINISTRATION].

Magnetic Resonance Imaging (MRI) Pare Burns

Transderm Scop contains an aluminized membrane. Pare burns accept been reported at the application site in patients wearing an aluminized transdermal system during an MRI scan. Remove Transderm Scop earlier undergoing an MRI.

Patient Counseling Information

Advise the patient to read the FDA-canonical patient labeling (PATIENT INFORMATION and Instructions for Utilise).

Administration Instructions

Counsel patients on how to utilize and remove the transdermal system [meet DOSAGE AND Assistants]:

• But clothing one transdermal system at whatsoever time.
• Practice not cut the transdermal system.
• Apply the transdermal system to the skin in the postauricular (hairless expanse backside one ear) area.
• After the transdermal organisation is applied on the dry peel backside the ear, wash hands thoroughly with soap and h2o and dry hands.
• If the transdermal system becomes displaced, discard the transdermal organisation, and utilise a new transdermal organization on the hairless surface area behind the other ear.
• Upon removal, fold the used transdermal system in half with the viscid side together, and discard in household trash in a manner that prevents accidental contact or ingestion by children, pets or others.

Patients With Open up-Bending Glaucoma

Advise patients with open up-angle glaucoma to remove the Transderm Scop transdermal system immediately and contact their healthcare provider if they experience symptoms of acute angle closure glaucoma, including pain and reddening of the optics, accompanied by dilated pupils, blurred vision and/or seeing halos around lights [see WARNINGS AND PRECAUTIONS].

Neuropsychiatric Adverse Reactions

• Advise patients that psychiatric agin reactions may occur, especially in patients with a past psychiatric history or in those receiving other drugs too associated with psychiatric furnishings, and to report to their healthcare provider any new or worsening psychiatric symptoms.
• Advise patients to discontinue Transderm Scop and contact a healthcare provider immediately if they feel a seizure.
• Propose patients, especially elderly patients, that cerebral impairment may occur during handling with Transderm Scop, specially in those receiving other drugs too associated with CNS effects, and to report to their healthcare provider if they develop signs or symptoms of cerebral impairment such every bit hallucinations, confusion or dizziness.
• Inform patients not to operate motor vehicles or other dangerous machinery or participate in underwater sports until they are reasonably certain that Transderm Scop does not impact them adversely [see WARNINGS AND PRECAUTIONS].

Decreased Gastrointestinal Motility And Urinary Retention

Instruct patients to remove the transdermal arrangement if they develop symptoms of intestinal obstacle (abdominal pain, nausea or vomiting) or any difficulties in urinating [see WARNINGS AND PRECAUTIONS].

Drug Withdrawal/Mail service-Removal Symptoms

Inform patients that if they remove the Transderm Scop transdermal system before handling is complete, withdrawal symptoms may occur and to seek firsthand medical care if they develop severe symptoms after removing Transderm Scop [meet WARNINGS AND PRECAUTIONS].

Blurred Vision

Inform patients that temporary dilation of the pupils and blurred vision may occur if Transderm Scop comes in contact with the eyes. Instruct patients to wash their easily thoroughly with soap and water immediately after handling the transdermal system [see DOSAGE AND ADMINISTRATION, WARNINGS AND PRECAUTIONS].

MRI Pare Burns

Instruct patients to remove the Transderm Scop transdermal system before undergoing an MRI [see WARNINGS AND PRECAUTIONS].

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Damage Of Fertility

No long-term studies in animals have been conducted to evaluate the carcinogenic potential of scopolamine. The mutagenic potential of scopolamine has not been evaluated.

Fertility studies were performed in female rats and revealed no prove of impaired fertility or harm to the fetus due to scopolamine hydrobromide administered by daily subcutaneous injection. Maternal trunk weights were reduced in the highest-dose group (plasma level approximately 500 times the level accomplished in humans using a transdermal system). However, fertility studies in male animals were not performed.

Use In Specific Populations

Pregnancy

Take a chance Summary

Bachelor data from observational studies and postmarketing reports with scopolamine use in pregnant women have not identified a drug associated risk of major nascence defects, miscarriage, or adverse fetal outcomes. Avoid utilise of Transderm Scop in pregnant women with severe preeclampsia considering eclamptic seizures have been reported after exposure to scopolamine (run into Data).

In brute studies, there was no evidence of agin developmental effects with intravenous assistants of scopolamine hydrobromide revealed in rats. Embryotoxicity was observed in rabbits at intravenous doses producing plasma levels approximately 100 times the levels accomplished in humans using a transdermal system.

The estimated background take a chance of major nativity defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of nascence defect, loss, or other agin outcomes. In the U.S. general population, the background gamble of major nascency defects and miscarriage in clinically recognized pregnancies is two% to 4% and fifteen% to twenty%, respectively.

Data

Human Data

Eclamptic Seizures

In published case reports, two meaning patients with severe preeclampsia were administered intravenous and intramuscular scopolamine, respectively, and developed eclamptic seizures shortly afterwards scopolamine administration [encounter WARNINGS AND PRECAUTIONS].

Animal Data

In animal reproduction studies, when pregnant rats and rabbits received scopolamine hydrobromide by daily intravenous injection, no agin effects were observed in rats. An embryotoxic effect was observed in rabbits at doses producing plasma levels approximately 100 times the levels achieved in humans using a transdermal system. Scopolamine administered parenterally to rats and rabbits at doses higher than the dose delivered by Transderm Scop did non affect uterine contractions or increase the duration of labor.

Lactation

Risk Summary

Scopolamine is present in human milk. There are no available data on the effects of scopolamine on the breastfed baby or the effects on milk production. Considering there accept been no consistent reports of adverse events in breastfed infants over decades of use, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Transderm Scop and whatsoever potential adverse furnishings on the breastfed kid from Transderm Scop or from the underlying maternal condition.

Pediatric Use

Safe and effectiveness in pediatric patients accept non been established. Pediatric patients are particularly susceptible to the agin reactions of scopolamine; including mydriasis, hallucinations, amblyopia and drug withdrawal syndrome. Neurologic and psychiatric adverse reactions, such as hallucinations, amblyopia and mydriasis accept also been reported.

Geriatric Apply

Clinical trials of Transderm Scop did non include sufficient number of subjects anile 65 years and older to make up one's mind if they respond differently from younger subjects. In other clinical experience, elderly patients had an increased risk of neurologic and psychiatric adverse reactions, such as hallucinations, confusion, dizziness and drug withdrawal syndrome [see WARNINGS AND PRECAUTIONS]. Consider more frequent monitoring for CNS adverse reactions during treatment with Transderm Scop in elderly patients [see WARNINGS AND PRECAUTIONS].

Renal Or Hepatic Impairment

Transderm Scop has not been studied in patients with renal or hepatic harm. Consider more frequent monitoring during treatment with Transderm Scop in patients with renal or hepatic harm because of the increased risk of CNS adverse reactions [see WARNINGS AND PRECAUTIONS].

Overdosage & Contraindications

OVERDOSE

The signs and symptoms of anticholinergic toxicity include: sluggishness, somnolence, coma, defoliation, agitation, hallucinations, convulsion, visual disturbance, dry out flushed skin, dry oral fissure, decreased bowel sounds, urinary retention, tachycardia, hypertension, and supraventricular arrhythmias. These symptoms tin can be astringent and may require medical intervention.

In cases of toxicity remove the Transderm Scop transdermal system. Serious symptomatic cases of overdosage involving multiple transdermal organisation applications and/or ingestion may be managed past initially ensuring the patient has an adequate airway and supporting respiration and apportionment. This should be speedily followed by removal of all transdermal systems from the skin and the rima oris. If there is evidence of transdermal system ingestion, endoscopic removal of swallowed transdermal systems, or administration of activated charcoal should be considered, equally indicated past the clinical situation. In whatever case where there is serious overdosage or signs of evolving acute toxicity, continuous monitoring of vital signs and ECG, establishment of intravenous admission, and assistants of oxygen are all recommended.

The signs and symptoms of overdose/toxicity due to scopolamine should be carefully distinguished from the occasionally observed syndrome of withdrawal [run into WARNINGS AND PRECAUTIONS]. Although mental confusion and dizziness may be observed with both acute toxicity and withdrawal, other characteristic findings differ: tachyarrhythmias, dry out skin, and decreased bowel sounds advise anticholinergic toxicity, while bradycardia, headache, nausea and intestinal cramps, and sweating suggest postal service-removal withdrawal.

If over-exposure occurs, call your Poison Control Center at 1-800-222-1222 for current information on the direction of poisoning or overdosage.

CONTRAINDICATIONS

Transderm Scop is contraindicated in patients with:

• angle closure glaucoma [meet WARNINGS AND PRECAUTIONS].
• hypersensitivity to scopolamine or other belladonna alkaloids or to whatsoever ingredient or component in the formulation or commitment system. Reactions have included rash generalized and erythema [run across Agin REACTIONS, DESCRIPTION].

CLINICAL PHARMACOLOGY

Mechanism Of Action

Scopolamine, a belladonna alkaloid, is an anticholinergic. Scopolamine acts: i) as a competitive inhibitor at postganglionic muscarinic receptor sites of the parasympathetic nervous arrangement, and ii) on smooth muscles that respond to acetylcholine but lack cholinergic innervation. Information technology has been suggested that scopolamine acts in the central nervous system (CNS) past blocking cholinergic manual from the vestibular nuclei to higher centers in the CNS and from the reticular germination to the airsickness center. Scopolamine tin inhibit the secretion of saliva and sweat, decrease gastrointestinal secretions and motility, cause drowsiness, dilate the pupils, increase center rate, and depress motor function.

Pharmacokinetics

The system is formulated to deliver approximately one mg of scopolamine to the systemic circulation over 3 days.

Absorption

Following application to the peel behind the ear, circulating plasma concentrations are detected within 4 hours with peak concentrations being obtained, on average, within 24 hours. The average plasma concentration produced is 87 pg/mL (0.28 nM) for free scopolamine and 354 pg/mL for total scopolamine (free + conjugates). Following removal of the used transdermal system, at that place is some degree of continued systemic assimilation of scopolamine bound in the pare layers.

Distribution

The distribution of scopolamine is not well characterized. It crosses the placenta and the blood brain barrier and may be reversibly bound to plasma proteins.

Elimination

Metabolism and Excretion

Scopolamine is metabolized and conjugated with less than v% of the full dose appearing unchanged in the urine. The enzymes responsible for metabolizing scopolamine are unknown. The exact emptying blueprint of scopolamine has not been determined. Following transdermal system removal, plasma concentrations of scopolamine turn down in a log linear style with an observed half-life of nine.five hours. Less than x% of the total dose is excreted in the urine as the parent drug and metabolites over 108 hours.

Drug Interaction Studies

An in vitro study using human hepatocytes examined the induction of CYP1A2 and CYP3A4 by scopolamine. Scopolamine did not induce CYP1A2 and CYP3A4 isoenzymes at the concentrations up to 10 nM. In an in vitro study using human being liver microsomes which evaluated the inhibition of CYP1A2, 2C8, 2C9, 2C19, 2D6 and 3A4, scopolamine did not inhibit these cytochrome P450 isoenzymes at the concentrations up to i micromolar. No in vivo drug-drug interaction studies accept been conducted.

Clinical Studies

Prevention Of Movement Sickness

In 195 developed subjects of unlike racial origins who participated in clinical efficacy studies at sea or in a controlled motion surround, there was a 75% reduction in the incidence of motion-induced nausea and vomiting. Transderm Scop was applied from 4 to xvi hours prior to the onset of motion in these studies.

Prevention Of Post-Operative Nausea And Vomiting

A clinical efficacy study evaluated 168 adult female patients undergoing gynecological surgery with anesthesia and opiate analgesia. Patients received Transderm Scop or placebo practical approximately 11 hours before anesthesia/opiate analgesia. No retching/vomiting during the 24-hour post-operative period was reported in 79% of those treated with Transderm Scop compared to 72% of those receiving placebo. When the need for boosted antiemetic medication was assessed during the same period, there was no demand for medication in 89% of patients treated with Transderm Scop as compared to 72% of placebo-treated patients.

PATIENT Data

Transderm Scop
(trans-derm skop)
(scopolamine) transdermal system

Read this Patient Data before you start using Transderm Scop and each time you lot get a refill. There may be new information. This information does non take the place of talking to your doctor well-nigh your medical status or your treatment.

What is Transderm Scop?

Transderm Scop is a prescription medicine used for adults to help prevent:

• nausea and vomiting from move sickness
• nausea and vomiting from anesthesia or taking opioid pain medicines after surgery

Information technology is non known if Transderm Scop is condom or effective in children.

Who should not use Transderm Scop?

Do not utilize Transderm Scop if y'all:

• have an eye problem called angle closure glaucoma.
• are allergic to scopolamine, belladonna alkaloids or any of the ingredients in Transderm Scop. Encounter the terminate of this leaflet for a listing of the ingredients in Transderm Scop. Ask your doc if y'all are not certain.

What should I tell my doctor before using Transderm Scop?

Earlier you employ Transderm Scop, tell your doctor about all of your medical conditions, including if you:

• take glaucoma (increased pressure in the eye).
• have a history of seizures or psychosis.
• have bug with your stomach or intestines.
• have problem urinating.
• are scheduled to have a gastric secretion test.
• have liver or kidney issues.
• are pregnant or plan to become pregnant. Information technology is not known if Transderm Scop can harm your unborn baby.
• are breastfeeding or plan to breastfeed. Transderm Scop tin pass into your breast milk and may harm your baby. Talk to your doctor well-nigh the best way to feed your baby if you use Transderm Scop.

Tell your md about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Transderm Scop may affect the way other medicines work, and other medicines may impact how Transderm Scop works. Medicines that yous accept by mouth may non be captivated well while y'all use Transderm Scop. Especially tell your doctor if you have:

• a sedative, hypnotic, opioid or anxiolytic (medicines that make you sleepy)
• an antidepressant medicine
• an anticholinergic medicine, such as an allergy or cold medicine, a medicine to treat float or bowel spasms, certain asthma medicines, or other medicines for movement sickness

Ask your doc if you are not sure if your medicine is one that is listed above.

Know the medicines you take. Proceed a list of them and show information technology to your doctor or pharmacist when you get a new medicine.

How should I use Transderm Scop?

• Come across the detailed Instructions for Use for information nearly how to use Transderm Scop at the terminate of this Patient Information leaflet.
• It is important that y'all apply Transderm Scop exactly as your doctor tells yous to.
• Your doctor may modify your Transderm Scop dose. Practice non modify your Transderm Scop dose without talking to your physician.
• Habiliment but one Transderm Scop at any time.
• If yous utilise besides much Transderm Scop, call your physician or Toxicant Control Center at 1-800-222-1222, or go to the nearest infirmary emergency room right away.

What should I avoid while using Transderm Scop?

• Yous should not drink alcohol while using Transderm Scop. Information technology tin can increase your chances of having serious side effects.
• Yous should not drive, operate heavy machinery, or do other dangerous activities until you lot know how Transderm Scop affects you.
• Yous should non utilize Transderm Scop during a Magnetic Resonance Imaging browse (MRI). Remove Transderm Scop before undergoing an MRI. It tin can cause your skin to fire.
• Y'all should be careful if you employ Transderm Scop while you lot participate in watersports because you lot may feel lost or confused (disoriented).
• Limit contact with water while pond and bathing because Transderm Scop may fall off. If Transderm Scop falls off, throw it away and apply a new ane on the hairless area behind your other ear.

What are the possible side effects of Transderm Scop?

Transderm Scop may cause serious side effects, including:

• angle closure glaucoma. If you take open up angle glaucoma and use Transderm Scop, remove Transderm Scop and phone call a doctor right away if you feel pain or discomfort, have blurred vision, or see halos or colored images around lights and reddening of your eyes.
• worsening of seizures. Tell your doctor about whatsoever worsening of seizures while using Transderm Scop.
• an unusual reaction chosen astute psychosis. Tell your doctor if you accept any of these symptoms:
  • confusion
  • agitation
  • rambling speech
  • hallucinations (seeing or hearing things that are non there)
  • paranoid behaviors and delusions (false belief in something)
• worsening of your preeclampsia during pregnancy. Some significant women with astringent preeclampsia have had seizures after getting scopolamine by injection in the musculus (intramuscular) or injection in the vein (intravenous).
• difficulty urinating.
• difficulties in food passing from the stomach to the modest intestines, which may cause abdominal pain, nausea or airsickness.
• withdrawal symptoms after removing Transderm Scop after using information technology for several days. Some people may have certain symptoms such as difficulty with residue, dizziness, nausea, airsickness, tum cramps, sweating, confusion, muscle weakness, low heart rate or depression claret pressure that could start 24 hours or more than later removing Transderm Scop. Call your doctor right away if your symptoms get astringent.
• temporary increase in the size of your pupil and blurry vision, peculiarly if Transderm Scop comes in contact with your eyes.
• pare burns at the site of Transderm Scop. This can happen during a medical test called a Magnetic Resonance Imaging scan (MRI). Transderm Scop contains aluminum and should exist removed from your peel before you have an MRI.

The nearly common side effects of using Transderm Scop include:

• dry out mouth
• blurred vision or centre problems
• feeling sleepy or drowsy
• disorientation (defoliation)
• dizziness
• feeling agitated or irritable
• pharyngitis (sore throat)

Tell your doctor if yous accept whatsoever side outcome that bothers y'all or that does not go away. These are not all the possible side furnishings of Transderm Scop.

Phone call your md for medical advice near side furnishings. You may written report side effects to FDA at 1-800-FDA-1088.

General information near the prophylactic and effective use of Transderm Scop.

Medicines are sometimes prescribed for purposes other than those listed in a patient information leaflet. Exercise not use Transderm Scop for a condition for which information technology was not prescribed. Practice not requite Transderm Scop to other people, even if they accept the same symptoms you have. It may harm them.

You tin ask your pharmacist or doc for information nigh Transderm Scop that is written for health professionals.

What are the ingredients in Transderm Scop?

Active ingredient: scopolamine

Inactive ingredients: light mineral oil, polyisobutylene, polypropylene and aluminized polyester film

INSTRUCTIONS FOR Apply

Transderm Scop
(trans-derm skop)
(scopolamine transdermal organisation)

Read this Instructions for Utilize earlier you start using Transderm Scop and each time you lot go a refill. There may be new information. This information does not have the place of talking to your doc nearly your medical condition or your handling.

Data most Transderm Scop:

• Transderm Scop is a tan-colored, circumvolve shaped transdermal arrangement (patch) with "Scopolamine 1 mg/three days" printed on it.
• Wear only one Transderm Scop at any time.
• Do not cut Transderm Scop.

To help prevent nausea and vomiting from motion sickness:

• Utilize one Transderm Scop to your peel on a hairless area behind i ear at least 4 hours before the activity to prevent nausea and vomiting.
• If the treatment is needed for longer than 3 days, remove Transderm Scop from the hairless area behind your ear. Get a new Transderm Scop and place it on the hairless area backside your other ear.

To aid prevent nausea and vomiting later on surgery:

• Follow your doctor'southward instructions about when to apply Transderm Scop before your scheduled surgery.
• Transderm Scop should be left in place for 24 hours later on surgery. After 24 hours, Transderm Scop should exist removed and thrown away.

How to use Transderm Scop:

Within the Transderm Scop package, you volition detect 1 Transderm Scop. An imprinted, tan bankroll membrane with a metal (silver) pasty surface is adhered to a clear, disposable release liner (See Effigy i).

1. Select a hairless area of skin behind one of your ears. Avoid areas on your skin that may have cuts, pain or tenderness. Wipe the area of your pare with a clean, dry tissue.
2. Cut along the dashed line on the Transderm Scop package to open up (Run across Figure ii).



3. Remove the clear plastic backing from the tan-colored round Transderm Scop (See Figure 3).



4. Do not touch the metallic adhesive (viscous) surface on Transderm Scop with your hands (Run into Figure four).



5. Utilize the metallic agglutinative surface of Transderm Scop firmly to the dry surface area of peel behind your ear. The imprinted, tan colored side of the transdermal system should be facing up and showing (See Figure 5). Wash your hands with soap and h2o right away later on applying Transderm Scop, so that any medicine from Transderm Scop that gets on your hands will not go into your eyes.

How to remove Transderm Scop:

Later on removing Transderm Scop, be sure to wash your hands and the surface area behind your ear thoroughly with soap and h2o. Please note that the used Transderm Scop will yet comprise some of the agile ingredient after employ. To avert accidental contact or ingestion by children, pets or others, fold the used Transderm Scop in one-half with the sticky side together. Throw away (dispose of) Transderm Scop in the household trash out of the reach of children, pets or others.

How should I store Transderm Scop?

• Shop Transderm Scop at room temperature between 68°F and 77°F (xx°C and 25°C) until you are ready to use it.
• Store Transderm Scop in an upright position.
• Practise not bend or roll Transderm Scop.

Keep Transderm Scop and all medicines out of reach of children.

The Medication Guide and Instructions for Use have been approved by the U.Southward. Food and Drug Assistants.

From

Written report Problems to the Food and Drug Administration

You are encouraged to report negative side furnishings of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

hayesandereliked.blogspot.com

Source: https://www.rxlist.com/transderm-scop-drug.htm

Share this post